Related references
Note: Only part of the references are listed.Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial
Filippo Pietrantonio et al.
TUMORI JOURNAL (2021)
Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram
A. Fernandez Montes et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study
Toshikazu Moriwaki et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study
Masayuki Nakashima et al.
CLINICAL COLORECTAL CANCER (2020)
Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects
Marissa Lam et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
Jean-Baptiste Bachet et al.
ESMO OPEN (2020)
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
Josep Tabernero et al.
ESMO OPEN (2020)
Real world aspects of palliative trifluridine plus tiperacil (TAS-102) in refractory metastatic colorectal cancer
Mikael Wallander et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2020)
A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer
Stig E. Andersen et al.
ACTA ONCOLOGICA (2019)
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis
Ana Fernandez Montes et al.
ONCOLOGIST (2019)
Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer
Alberto Carmona-Bayonas et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
Daisuke Kotani et al.
BMC CANCER (2019)
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
Johannes J. M. Kwakman et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO
E. Dell'Aquila et al.
ANNALS OF ONCOLOGY (2018)
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
Eric Van Cutsem et al.
EUROPEAN JOURNAL OF CANCER (2018)
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
F. Pietrantonio et al.
ANNALS OF ONCOLOGY (2017)
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
A. Custodio et al.
BRITISH JOURNAL OF CANCER (2017)
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program (vol 16, 412, 2016)
Antoine Adenis et al.
BMC CANCER (2016)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Holly G. Prigerson et al.
JAMA ONCOLOGY (2015)
External validity: the neglected dimension in evidence ranking
Navindra Persaud et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2006)
Statistics notes - The cost of dichotomising continuous variables
DG Altman et al.
BRITISH MEDICAL JOURNAL (2006)
Exclusion criteria used in antidepressant efficacy trials - Consistency across studies and representativeness of samples included
M Zimmerman et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2004)
Share Paper
